Antipsychotic Side Effects: What to Expect, What to Watch For, and What to Do
Written by Vaishali Desai, PMHNP-BC · Updated July 25, 2026
Hub: Medication Guides
Antipsychotics are prescribed for schizophrenia, bipolar disorder, treatment-resistant depression, OCD augmentation, Tourette syndrome, and other conditions. They are among the most effective medications in psychiatry — and they have some of the most clinically significant side effect profiles. Patients deserve to understand both of those things before their first fill, not after their first 20-lb weight gain or their first episode of inner restlessness they can't explain.
Side effects are the leading reason people stop antipsychotics. Most of those discontinuations are preventable — through medication selection, early monitoring, and having the right conversations. This guide covers the side effects that matter most, what to watch for, and what to do.
Extrapyramidal Symptoms (EPS): What They Are and Why They Happen
EPS are movement-related side effects caused by dopamine blockade in the basal ganglia. They are more common with first-generation antipsychotics (FGAs) but can occur with any dopamine-blocking medication. There are four distinct EPS presentations:
Akathisia
Akathisia is profound inner restlessness — a subjective sense of needing to move, an inability to sit still, constant urges to pace or shift position. It is one of the most distressing medication side effects patients experience, and it is critically underdiagnosed. The reason: patients describe it as “anxiety” or “agitation,” and prescribers chart it as anxiety or agitation — and sometimes respond by increasing the antipsychotic dose. That is the wrong direction. Increasing the dose worsens akathisia.
When akathisia is severe, it is a clinical emergency — it is associated with suicidality and treatment refusal. Treatment options: propranolol 10–30 mg, mirtazapine 7.5–15 mg, benztropine, or dose reduction/switch. If a patient on an antipsychotic reports inner restlessness or inability to sit still, akathisia must be ruled out before assuming it is anxiety.
Acute Dystonia
Sudden involuntary muscle contractions — most commonly of the neck (torticollis), jaw, eyes (oculogyric crisis), or tongue. Occurs within the first days of starting a high-potency antipsychotic. It is frightening, painful, and rapidly reversible with IM or IV benztropine or diphenhydramine. If this happens, go to the emergency room. Risk is highest in young men on high-potency FGAs.
Drug-Induced Parkinsonism
Tremor (resting, pill-rolling), rigidity, shuffling gait, bradykinesia, and masked facies — symptoms indistinguishable from Parkinson's disease. Caused by striatal dopamine blockade. Responds to dose reduction, switch to a lower-EPS agent, or anticholinergic medications (benztropine, trihexyphenidyl).
Tardive Dyskinesia (TD)
TD is the most serious EPS because it is often irreversible. Repetitive, involuntary movements — typically oro-facial (lip-smacking, tongue thrusting, chewing), but also of the limbs and trunk. TD develops after months to years of antipsychotic exposure and is caused by dopamine receptor supersensitivity from chronic blockade.
Risk is cumulative and exposure-dependent. First-generation antipsychotics carry significantly higher TD risk than second-generation agents. Clozapine has the lowest TD risk of any antipsychotic. The AIMS (Abnormal Involuntary Movement Scale) is the standard monitoring tool — prescribers should administer it at every visit for patients on long-term antipsychotics. Two FDA-approved treatments for TD exist: valbenazine (Ingrezza) and deutetrabenazine (Austedo) — both VMAT2 inhibitors that reduce involuntary movements.
Metabolic Effects: Weight, Glucose, and Lipids
Metabolic side effects are the most clinically significant long-term concern with many second-generation antipsychotics. The mechanisms are multiple: H1 histamine blockade drives appetite and sedation; 5-HT2C antagonism removes satiety signaling; D2 blockade contributes to insulin resistance and dyslipidemia independent of caloric intake.
Olanzapine and clozapine carry the highest metabolic burden — average weight gain of 6–10 kg in the first 6 months is common, with significant increases in fasting glucose, HbA1c, and triglycerides. Quetiapine and risperidone carry moderate metabolic risk. Aripiprazole, lurasidone, and ziprasidone have substantially lower metabolic profiles and are the preferred options when weight gain is a significant concern.
Monitoring Schedule
Current guidelines recommend: weight and BMI at baseline, 4 weeks, 8 weeks, and 12 weeks, then quarterly; fasting glucose and lipids at baseline, 12 weeks, and annually; waist circumference at baseline and annually; blood pressure at baseline and 12 weeks. This monitoring is standard of care — not optional. If your prescriber is not performing it, ask why.
Management Options
- Metformin 500–1000 mg has a meaningful evidence base for reducing antipsychotic-associated weight gain, particularly for olanzapine and clozapine.
- GLP-1 receptor agonists (semaglutide, liraglutide) are generating significant interest for antipsychotic-related weight gain — emerging evidence is promising.
- Exercise — particularly resistance training — has specific metabolic benefits: improved insulin sensitivity and preserved muscle mass during weight gain.
- Medication switch to a lower-metabolic-risk antipsychotic is sometimes the right clinical answer. If you have gained significant weight or developed metabolic abnormalities, this conversation is worth having explicitly.
Written by a PMHNP-BC
Starting Psychiatric Medication: What to Expect
A week-by-week guide to what actually happens in your body when you begin a new psychiatric medication — and how to talk to your prescriber when something feels off. Written by Vaishali Desai, PMHNP-BC, DNP.
⚡ Instant download — available immediately after purchase
Other Important Side Effects
QTc Prolongation
Some antipsychotics — particularly haloperidol (Haldol), ziprasidone (Geodon), and iloperidone (Fanapt) — prolong the QTc interval on ECG, increasing risk of serious cardiac arrhythmias. In high-risk patients (baseline QTc >450ms, other QT-prolonging medications, hypokalemia, hypomagnesemia, family history of sudden cardiac death), a baseline ECG and follow-up monitoring are warranted. Discuss your cardiac history with your prescriber before starting any antipsychotic.
Prolactin Elevation
D2 blockade in the pituitary raises prolactin — the hormone that stimulates breast milk production. Elevated prolactin can cause amenorrhea, galactorrhea (nipple discharge), sexual dysfunction, reduced libido, and long-term bone density loss with chronic elevation. Risperidone and haloperidol cause the highest prolactin elevations. Aripiprazole and quetiapine are relatively prolactin-sparing — aripiprazole's partial agonist mechanism actually tends to lower prolactin. If you are experiencing menstrual changes, galactorrhea, or sexual side effects, ask your prescriber to check a prolactin level.
Sedation
Sedation from antipsychotics is often desired in acute agitation or for sleep — and becomes a treatment barrier long-term when it persists as daytime drowsiness. Quetiapine and clozapine are the most sedating second-generation antipsychotics. A simple timing adjustment — switching from morning to bedtime dosing — converts sedation from a daytime liability into a sleep benefit. If you are taking a sedating antipsychotic in the morning and struggling with daytime drowsiness, ask about this.
Clozapine: Special Considerations
Clozapine is the most effective antipsychotic available — reserved for treatment-resistant schizophrenia because of its unique side effect profile, not because it is less effective. Key considerations:
- Agranulocytosis: rare but potentially fatal reduction in white blood cells. Requires mandatory ANC (absolute neutrophil count) monitoring through the REMS program — weekly for the first 6 months, biweekly for 6 months, then monthly.
- Myocarditis: risk is highest in the first 4–6 weeks of treatment. Patients should be monitored for flu-like symptoms, chest pain, and tachycardia — a baseline CRP and troponin with follow-up monitoring is standard practice.
- Sialorrhea: excessive salivation, often most noticeable at night. Atropine eye drops sublingually or glycopyrrolate can help. This is benign but affects quality of life and adherence.
Clinical Note 1: Akathisia is undertreated because it is systematically mistaken for anxiety and agitation. The clinical distinction matters enormously — escalating the antipsychotic for “anxiety” in a patient with akathisia makes it worse, sometimes dramatically so. Ask specifically: “Do you feel inner restlessness or an urge to move?” Not “Are you feeling anxious?” — the patient may not connect the inner restlessness to anxiety because it is qualitatively different from how they experience anxiety. If a patient on an antipsychotic describes needing to move, inability to sit through a meal, or constant urge to pace, that is akathisia until proven otherwise. — Vaishali Desai, PMHNP-BC
Clinical Note 2: Metabolic monitoring for antipsychotics is nationally underperformed — studies consistently show fewer than 20% of patients newly started on antipsychotics receive recommended baseline metabolic labs. The solution is not to rely on annual wellness visits or to assume someone else is doing it. Set calendar reminders at the time of prescribing: 4-week weight check, 12-week fasting labs. If you prescribe antipsychotics and you don't have a monitoring trigger system, your patients are not getting standard of care. The consequence of unmonitored antipsychotic metabolic effects — accelerated cardiovascular disease, new-onset diabetes — accumulates silently until it is clinically significant. — Vaishali Desai, PMHNP-BC
Prescriber's Note — Vaishali Desai, PMHNP-BC
Have the TD and metabolic side effect conversation at initiation, at every 3-month visit for the first year, and annually thereafter — and document it. Not because you are checking a box, but because a patient who was warned about TD and had it explained — what it looks like, when it might develop, that there are approved treatments if it occurs — is far more likely to report early symptoms and stay engaged in monitoring. A patient who develops TD without ever having been told it was possible feels blindsided and mistrusted. The same is true for metabolic effects. Informed consent is not a one-time event at initiation; it is an ongoing clinical conversation that needs to be documented as such.
Related Resources
Vaishali Desai, PMHNP-BC, DNP is a Board-Certified Psychiatric Mental Health Nurse Practitioner with nearly 10 years of clinical experience in mental health. She is the founder of 360 Mental Healing LLC and 360 Mind Shop, created to give patients and families the clinical information they deserve in language they can actually use.
This content is for informational purposes only and does not constitute medical advice, a clinical assessment, or a provider-patient relationship. Always consult your licensed healthcare provider before starting, stopping, or changing any medication or treatment plan. If you are experiencing a psychiatric or medical emergency, call 911 or go to your nearest emergency room.
Psychiatric Medication Guides — Written by a PMHNP-BC
What to expect when starting psychiatric medication — and a complete guide to understanding bipolar disorder and your medication options. Instant download.